EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSLAFG00000027679
Gene Symbol: KCNQ2
2 External references
248 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSLAFG00000005689
Gene Symbol: KCNQ3
2 External references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Presenilin 1

Ensembl ID : ENSLAFG00000001076
Gene Symbol: PSEN1
2 External references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Presenilin 2

Ensembl ID : ENSLAFG00000007445
Gene Symbol: PSEN2
2 External references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSLAFG00000025722
Gene Symbol: PSENEN
2 External references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin D2 Receptor

Ensembl ID : ENSLAFG00000009971
Gene Symbol: PTGDR
2 External references
118 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin D2 Receptor 2

Ensembl ID : ENSLAFG00000009452
Gene Symbol: PTGDR2
2 External references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin E Receptor 1

Ensembl ID : ENSLAFG00000030343
Gene Symbol: PTGER1
2 External references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin E Receptor 2

Ensembl ID : ENSLAFG00000027078
Gene Symbol: PTGER2
2 External references
241 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin E Receptor 3

Ensembl ID : ENSLAFG00000018598
Gene Symbol: PTGER3
2 External references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin E Receptor 4

Ensembl ID : ENSLAFG00000017781
Gene Symbol: PTGER4
2 External references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin F Receptor

Ensembl ID : ENSLAFG00000005183
Gene Symbol: PTGFR
2 External references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).